This webinar explores how the field of hematological research is pivoting toward a unified whole genome sequencing (WGS) approach, providing a more comprehensive understanding of the complex genomics and biological drivers that define AML.
Key Learning Objectives:
Learn the mechanistic and clinical significance of WGS-derived findings from the MEASURE–ATLAS study, including pathogenic variants systematically missed by SOC testing.
Understand how whole genome interrogation uncovers new biological insights, including inherited predispositions and underrecognized structural variants with prognostic or therapeutic implications.
Evaluate the technical and computational requirements for deploying a fully integrated WGS-based hematologic malignancy research workflow.
Explore how Illumina’s unified ecosystem enables laboratories to generate high-resolution, end-to-end genomic profiles that materially elevate confidence and research output.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
